635 related articles for article (PubMed ID: 26517679)
1. Targeting stemness is an effective strategy to control EML4-ALK+ non-small cell lung cancer cells.
Oh SJ; Noh KH; Lee YH; Hong SO; Song KH; Lee HJ; Kim S; Kim TM; Jeon JH; Seo JH; Kim DW; Kim TW
Oncotarget; 2015 Nov; 6(37):40255-67. PubMed ID: 26517679
[TBL] [Abstract][Full Text] [Related]
2. ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
[TBL] [Abstract][Full Text] [Related]
3. HIP1-ALK, a novel ALK fusion variant that responds to crizotinib.
Fang DD; Zhang B; Gu Q; Lira M; Xu Q; Sun H; Qian M; Sheng W; Ozeck M; Wang Z; Zhang C; Chen X; Chen KX; Li J; Chen SH; Christensen J; Mao M; Chan CC
J Thorac Oncol; 2014 Mar; 9(3):285-94. PubMed ID: 24496003
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Katayama R; Khan TM; Benes C; Lifshits E; Ebi H; Rivera VM; Shakespeare WC; Iafrate AJ; Engelman JA; Shaw AT
Proc Natl Acad Sci U S A; 2011 May; 108(18):7535-40. PubMed ID: 21502504
[TBL] [Abstract][Full Text] [Related]
5. Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins.
Kang CH; Yun JI; Lee K; Lee CO; Lee HK; Yun CS; Hwang JY; Cho SY; Jung H; Kim P; Ha JD; Jeon JH; Choi SU; Jeong HG; Kim HR; Park CH
Biochem Biophys Res Commun; 2015 Aug; 464(3):762-7. PubMed ID: 26168728
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effects of crizotinib and radiotherapy in experimental EML4-ALK fusion positive lung cancer.
Dai Y; Wei Q; Schwager C; Moustafa M; Zhou C; Lipson KE; Weichert W; Debus J; Abdollahi A
Radiother Oncol; 2015 Feb; 114(2):173-81. PubMed ID: 25592111
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4-ALK-Positive Human Non-Small Cell Lung Cancer.
Pyo KH; Lim SM; Kim HR; Sung YH; Yun MR; Kim SM; Kim H; Kang HN; Lee JM; Kim SG; Park CW; Chang H; Shim HS; Lee HW; Cho BC
J Thorac Oncol; 2017 Mar; 12(3):491-500. PubMed ID: 27836576
[TBL] [Abstract][Full Text] [Related]
8. miR-100-5p confers resistance to ALK tyrosine kinase inhibitors Crizotinib and Lorlatinib in EML4-ALK positive NSCLC.
Lai Y; Kacal M; Kanony M; Stukan I; Jatta K; Kis L; Norberg E; Vakifahmetoglu-Norberg H; Lewensohn R; Hydbring P; Ekman S
Biochem Biophys Res Commun; 2019 Apr; 511(2):260-265. PubMed ID: 30791979
[TBL] [Abstract][Full Text] [Related]
9. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.
Mori M; Ueno Y; Konagai S; Fushiki H; Shimada I; Kondoh Y; Saito R; Mori K; Shindou N; Soga T; Sakagami H; Furutani T; Doihara H; Kudoh M; Kuromitsu S
Mol Cancer Ther; 2014 Feb; 13(2):329-40. PubMed ID: 24419060
[TBL] [Abstract][Full Text] [Related]
10. ALK inhibitor PF02341066 (crizotinib) increases sensitivity to radiation in non-small cell lung cancer expressing EML4-ALK.
Sun Y; Nowak KA; Zaorsky NG; Winchester CL; Dalal K; Giacalone NJ; Liu N; Werner-Wasik M; Wasik MA; Dicker AP; Lu B
Mol Cancer Ther; 2013 May; 12(5):696-704. PubMed ID: 23443800
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of ALK kinase splicing isoforms in non-small-cell lung cancer.
de Figueiredo-Pontes LL; Wong DW; Tin VP; Chung LP; Yasuda H; Yamaguchi N; Nakayama S; Jänne PA; Wong MP; Kobayashi SS; Costa DB
J Thorac Oncol; 2014 Feb; 9(2):248-53. PubMed ID: 24419423
[TBL] [Abstract][Full Text] [Related]
12. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
[TBL] [Abstract][Full Text] [Related]
13. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.
Taniguchi H; Takeuchi S; Fukuda K; Nakagawa T; Arai S; Nanjo S; Yamada T; Yamaguchi H; Mukae H; Yano S
Cancer Sci; 2017 Jan; 108(1):53-60. PubMed ID: 27783866
[TBL] [Abstract][Full Text] [Related]
14. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
[TBL] [Abstract][Full Text] [Related]
15. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
[TBL] [Abstract][Full Text] [Related]
16. EML4-ALK induces epithelial-mesenchymal transition consistent with cancer stem cell properties in H1299 non-small cell lung cancer cells.
Guo F; Liu X; Qing Q; Sang Y; Feng C; Li X; Jiang L; Su P; Wang Y
Biochem Biophys Res Commun; 2015 Apr; 459(3):398-404. PubMed ID: 25735977
[TBL] [Abstract][Full Text] [Related]
17. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.
Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L
Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400
[TBL] [Abstract][Full Text] [Related]
18. Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer.
Woo CG; Seo S; Kim SW; Jang SJ; Park KS; Song JY; Lee B; Richards MW; Bayliss R; Lee DH; Choi J
Ann Oncol; 2017 Apr; 28(4):791-797. PubMed ID: 28039177
[TBL] [Abstract][Full Text] [Related]
19. Rearranged EML4-ALK fusion transcripts sequester in circulating blood platelets and enable blood-based crizotinib response monitoring in non-small-cell lung cancer.
Nilsson RJ; Karachaliou N; Berenguer J; Gimenez-Capitan A; Schellen P; Teixido C; Tannous J; Kuiper JL; Drees E; Grabowska M; van Keulen M; Heideman DA; Thunnissen E; Dingemans AM; Viteri S; Tannous BA; Drozdowskyj A; Rosell R; Smit EF; Wurdinger T
Oncotarget; 2016 Jan; 7(1):1066-75. PubMed ID: 26544515
[TBL] [Abstract][Full Text] [Related]
20. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]